The “Guangdong-Hong Kong-Macao Greater Bay Area Anti-Tumor Drug R&D and Evaluation Center” is co-founded by Lewwin Pharm, the Cancer Research Center of the Hong Kong University of Science and Technology (HKUST), and the laboratory of Professor Chun Liang from the Division of Life Science at HKUST. This initiative integrates the comprehensive advantages of both parties’ key technology platforms in areas including anti-tumor target research, anti-tumor mechanism studies, anti-tumor drug screening, non-clinical pharmacodynamic evaluation of anti-tumor drugs, pharmacokinetic research, safety evaluation, and pharmaceutical research. The collaboration aims to enhance both parties’ capabilities in anti-tumor drug research, development, and innovation; strengthen their innovation capacity and R&D capabilities in the anti-tumor drug field; and advance the comprehensive development of anti-tumor drugs. It also seeks to facilitate the transformation of research outcomes from HKUST's Division of Life Science and Cancer Research Center, turning “innovative ideas” into “innovative products”.

Currently, multiple anti-tumor drugs are undergoing druggability evaluation and screening in the Center. EN002, an original Class 1 innovative drug with a globally novel target developed in collaboration with the Hong Kong University of Science and Technology, has obtained clinical trial implied approval from the CDE and has been established in Guangzhou.